Current Alzheimer's disease clinical trials: Methods and placebo outcomes

Alzheimer's and Dementia

Volumn 5, Issue 5, 2009, Pages 388-397

  Schneider, Lon S ^a   Sano, Mary ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Activities of daily living; Alzheimer's disease; Alzheimer's Disease Assessment Scale (ADAS); Amyloid beta protein; Cholinesterase inhibitors; Clinical Dementia Rating scale; Clinical global impression of change; Clinical trials; Clinical trials methods; Memantine

Indexed keywords

AAC 001; ACC 001 VACCINE; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALZHEIMER DISEASE VACCINE; ATORVASTATIN; AZD 103; BAPINEUZUMAB; CHOLINESTERASE INHIBITOR; DOCOSAHEXAENOIC ACID; ELND 005; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; IMMUNOGLOBULIN; INOSITOL DERIVATIVE; MEMANTINE; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PF 04360365; PF 04494700; PF 4360365; PLACEBO; QS 21; SCYLLO INOSITOL; SEMAGACESTAT; SIMVASTATIN; TARENFLURBIL; TTP 448; UNCLASSIFIED DRUG; VITAMIN B GROUP; XALIPRODEN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DATA ANALYSIS; DEMOGRAPHY; DETERIORATION; DISEASE SEVERITY; FOLLOW UP; GENOTYPE; HUMAN; INFORMATION RETRIEVAL; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; SAMPLE SIZE; SCORING SYSTEM; TREATMENT DURATION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; MALE; MEMANTINE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; TREATMENT OUTCOME;

EID: 69949123520     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2009.07.038     Document Type: Article

References (34)

1. Leber P. What is the evidence that a dementia treatment works? criteria used by drug regulatory authorities. In: Qizilbash N., Schneider L.S., Chui H., et al. (Eds). Evidence-based dementia practice (2003), Blackwells, Oxford, UK 376-387
2. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. Available at: http://www.emea.europa.eu/pdfs/human/ewp/055395en.pdf. Accessed May 5, 2009.
3. Schneider LS. Issues in design and conductance of clinical trials for cognitive-enhancing drugs. In: Animal and translational models of behavioural disorders. In: McArthur RA, Borsini F, eds. Neurological disorders. Volume 2. New York: Elsevier; 2008.
4. Schneider L.S. Prevention therapeutics of dementia. Alzheimers Dementia 4 (2008) S122-S130
5. Mohs R.C., Kawas C., and Carillo M.C. Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimers Dementia 2 (2006) 131-139
6. Vellas B., Andrieu S., Sampaio C., and Wilcock G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 6 (2007) 56-62
7. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
8. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993) 2412-2414
9. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 11 Suppl 2 (1997) S22-S32
10. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 Suppl. (1997) 33S-39S
11. Gelinas I., Gauthier L., McIntyre M., and Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 53 (1999) 471-481
12. Anonymous. PhRMA Web Synopsis: protocol A2581078 01 June 2008 Final-an 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease. Available at: http://pdf.clinicalstudyresults.org/documents/company-study_4374_0.pdf. Accessed April 15, 2009.
13. Sano M. Multi-center, randomized, double-blind, placebo-controlled trial of simvastatin to slow the progression of Alzheimer's disease: Alzheimer's Association International Conference on Alzheimer's Disease, Chicago, IL, July 26-31, 2008. Alzheimers Dementia 2008;4(Suppl 2):T200.
14. Aisen P.S., Schneider L.S., Sano M., et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300 (2008) 1774-1783
15. Gauthier S., Douillet P., Doody R., Fox N.C., and Orgogozo J.M. Effect of xaliproden, a compound with neurotrophic properties, on the progression of Alzheimer's disease: results of two large 18-month studies assessing clinical efficacy and cerebral atrophy. Presentation and poster, Clinical Trials in Alzheimer's Disease (September 17-19, 2008), France, Montpellier
16. Saumier D. Lessons learned in trial design: the ALZHEMEDTM (Tramiprosate) experience. Alzheimer's Association Research Roundtable, Washington, DC, Oct 2008.
17. Green RC, Schneider LS, Hendrix SB, et al. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multi-center phase III trial-Alzheimer's Association International Conference on Alzheimer's Disease, Chicago, IL July 26-31, 2008. Alzheimers Dementia 2008;4(Suppl 1): P86.
18. Gilman S. Phase II trial of bapieumuzab for Alzheimer's disease: Alzheimer's Association International Conference on Alzheimer's Disease, Chicago, IL, July 26-31, 2008. Alzheimers Dementia 2008;4(Suppl 2):T166.
19. Wilcock GK, Black SE, Balch AH, et al. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month international multi-center phase 3 trial-Alzheimer's Association International Conference on Alzheimer's Disease. Vienna, Austria, July 13-16, 2009. Alzheimers Dementia 2009;5(Suppl 1):P86.
20. Quinn J.F., Raman R., Thomas R., et al. Omega 3 fatty acids and Alzheimer's disease: trial design and baseline study population characteristics in a clinical trial of docosahexanoic acid for Alzheimer's disease. Alzheimers Dementia 4 Suppl 1 (2008) T773
21. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimers disease: report of the NINCDS-AD Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34 (1984) 939-944
22. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
23. L. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997;278:1349-56.
24. Harrison J., Minassian S.L., Jenkins L., Black R.S., Koller M., and Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64 (2007) 1323-1329
25. Mohs R.C., Knopman D., Petersen R.C., et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale (ADAS) that broaden its scope. Alzheimer Dis Assoc Disord 11 (1997) S13-S21
26. Schneider LS, Dagerman KS, Shaikh Z, Insel P. No secular trend and high variability for ADAS-cog change among placebo groups from clinical trials: Alzheimer's Association International Conference on Alzheimer's Disease, Chicago, IL, July 26-31, 2008. Alzheimers Dementia 2008;4(Suppl 2):T167.
27. Anonymous. FDA rejects wider application of Forest Labs Alzheimer's drug. The Wall Street Journal, July 25, 2005. Available at: http://online.wsj.com/article/SB112231577567995101.html?mod=googlewsj.
28. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
29. Feldman H.H., Ferris S., Winblad B., et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6 (2007) 501-512
30. Winblad B., Gauthier S., Scinto L., et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70 (2008) 2024-2035
31. Cortes F., Portet F., Touchon J., and Vellas B. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?. J Nutr Health Aging 11 (2007) 330-337
32. Vellas B., Andrieu S., Sampaio C., et al. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 7 (2008) 436-450
33. Vellas B., Andrieu S., Cantet C., Dartigues J., and Gauthier S. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?. J Nutr Health Aging 11 (2007) 338-341
34. Sampaio C. Clinical relevance on Alzheimer's disease endpoints. J Nutr Health Aging 11 (2007) 316-317